| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/12/2002 | US20020128267 Especially celecoxib, deracoxib, valdecoxib, a benzopyran COX-2 inhibitor, parecoxib, rofecoxib etoricoxib, or a 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl) -substituted cyclopentenone, or pyridazinone |
| 09/12/2002 | US20020128266 ABCA-1 elevating compounds |
| 09/12/2002 | US20020128263 Treatment or prevention of mGluR5 receptor mediated disorders. |
| 09/12/2002 | US20020128262 Styrylbenzodiazepines |
| 09/12/2002 | US20020128252 Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use |
| 09/12/2002 | US20020128249 Phthalocyanine analogs |
| 09/12/2002 | US20020128247 Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents |
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128231 Aryl-indane compounds |
| 09/12/2002 | US20020128230 Neutrophil function inhibitors |
| 09/12/2002 | US20020128223 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 09/12/2002 | US20020128222 Methods to enhance wound healing and enhanced wound coverage material |
| 09/12/2002 | US20020128220 Testosterone-repressed prostate message-2 (TRPM-2); delaying progression of prostatic tumor cells to an androgen-independent state |
| 09/12/2002 | US20020128216 Antisense oligonucleotides and peptide nucleic acids for treating asthma or an eosinophilic syndrome |
| 09/12/2002 | US20020128200 Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals |
| 09/12/2002 | US20020128193 Retro-inverso prosaposin-derived peptides and use thereof |
| 09/12/2002 | US20020128183 Gene regulation therapy involving ferritin |
| 09/12/2002 | US20020128173 Method of treating or preventing migraine headaches |
| 09/12/2002 | US20020127689 Novel human galectins |
| 09/12/2002 | US20020127676 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/12/2002 | US20020127634 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 09/12/2002 | US20020127612 Cell proliferation polypeptide for use in the diagnosis and treatment of tumors |
| 09/12/2002 | US20020127605 Cyclophilin compound for use in the treatment of infections, nervous system, skin, ischemic and vision disorders |
| 09/12/2002 | US20020127558 Genetic polymorphism of MxA protein and use thereof |
| 09/12/2002 | US20020127553 Apoptin-associating protein |
| 09/12/2002 | US20020127540 Detecting modulators of bone morphogenic activities; obtain cells, incubate with modulator, monitor expression of reporter molecules, compare to control |
| 09/12/2002 | US20020127248 Using rapamycin compound for therapy and prophylaxis of neointimal proliferation and thickening |
| 09/12/2002 | US20020127243 Administering dietary supplement comprising soybean, mushroom and mung bean or extracts to ameliorate at least one effect of malignancy or viral infection |
| 09/12/2002 | US20020127230 Transcutaneous photodynamic therapy ("PDT") of a target tissue |
| 09/12/2002 | US20020127227 Antagonist monoclonal antibodies (mAb) that bind to the RHAMM (receptor for hyaluronic acid mediated motility) receptor; useful for preventing proliferative disease states in a mammal |
| 09/12/2002 | US20020127222 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| 09/12/2002 | US20020127211 Increasing or facilitating absorption of minerals from diet using enteral nutritional composition which includes lactobacilli |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | US20020127182 Paramagnetic metal ion-based macrocylic magnetization transfer contrast agents and method of use |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | DE10111058A1 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten New pharmaceutical compositions based on anticholinergics and NK¶1¶ receptor antagonists |
| 09/12/2002 | DE10110749A1 Substituierte Aminodicarbonsäurederivate Substituted Aminodicarbonsäurederivate |
| 09/12/2002 | DE10110747A1 Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use |
| 09/12/2002 | DE10109855A1 Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung Polypeptide of a p53 protein specific murine alpha / beta T-cell receptor nucleic acids encoding these, and their use |
| 09/12/2002 | DE10109813A1 Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen Tumor antigen peptide from human MDM2 proto-oncogene |
| 09/12/2002 | DE10108851A1 Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten Use of 5'-substituted nucleosides and / or their prodrugs for the resistance-free therapy of infectious diseases |
| 09/12/2002 | CA2743731A1 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 09/12/2002 | CA2445018A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | CA2445004A1 Polypeptides of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids encoding these and their use |
| 09/12/2002 | CA2442396A1 Method and formula for anti-tumor and anti-matastatic effect |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2440141A1 Compounds and methods for the treatment of urogenital disorders |
| 09/12/2002 | CA2440100A1 New use |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439939A1 Novel aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439933A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | CA2439926A1 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| 09/12/2002 | CA2439917A1 Compositions having improved bioavailability of eletriptan |
| 09/12/2002 | CA2439915A1 New pharmaceutical compositions based on anticholinergics and nk1-receptor antagonists |
| 09/12/2002 | CA2439859A1 N-but-3-enyl norbuprenorphine and its use as analgesic |
| 09/12/2002 | CA2439852A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | CA2439849A1 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | CA2439827A1 Peptide deformylase inhibitors |
| 09/12/2002 | CA2439811A1 Method of treating tumor and consignment system of proliferating and processing activated lymphocytes to be used in parallel to pdt |
| 09/12/2002 | CA2439759A1 Substituted amino dicarboxylic acid derivatives |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439666A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| 09/12/2002 | CA2439644A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours |
| 09/12/2002 | CA2439636A1 Mouse cytokine receptor |
| 09/12/2002 | CA2439628A1 Vaccine |
| 09/12/2002 | CA2439581A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438829A1 Methods for preparing new taxoids and pharmaceutical compositions containing them |
| 09/12/2002 | CA2438737A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | CA2438623A1 Extracorporeal blood processing information management system |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2437259A1 Plant extracts and compositions comprising extracellular protease inhibitors |
| 09/12/2002 | CA2434601A1 Methods for specifically inhibiting histone deacetylase-4 |
| 09/12/2002 | CA2434184A1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2433933A1 Use of lp82 to treat hematopoietic disorders |
| 09/12/2002 | CA2433467A1 Substituted quinolinecarboxamides as antiviral agents |
| 09/12/2002 | CA2432280A1 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1239043A2 Fusion proteins comprising tumour necrosis factor receptor |
| 09/11/2002 | EP1239033A1 Semaphorin receptor |
| 09/11/2002 | EP1238978A2 Intermediates for the synthesis of radiolabelled tropanes |
| 09/11/2002 | EP1238678A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/11/2002 | EP1238674A2 Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF |
| 09/11/2002 | EP1238669A2 Neutrophil function inhibitors which contain glucosamine |
| 09/11/2002 | EP1238668A1 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof |
| 09/11/2002 | EP1238095A2 Compositions and methods for caspase-induced apoptosis |
| 09/11/2002 | EP1238080A2 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 09/11/2002 | EP1238075A2 Chordin-like molecules and uses thereof |
| 09/11/2002 | EP1238070A2 Therapeutically useful synthetic oligonucleotides |
| 09/11/2002 | EP1238066A2 Masp-3, a complement-fixing enzyme, and uses for it |